https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%B3%BD%E6%82%A6
泽悦 - 版本历史
2026-04-18T09:03:08Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%B3%BD%E6%82%A6&diff=313436&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T03:03:07Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[泽悦]]([[Zeyue]])</strong>，通用名为<strong>[[盐酸杰克替尼]]([[Jaktinib Hydrochloride]])</strong>，是由中国<strong>[[泽璟制药]]([[Zelgen]])</strong>自主研发的一种新型、口服强效<strong>[[JAK抑制剂]]</strong>。作为2026年血液学与自免领域的一线治疗药物，[[泽悦]]通过高选择性地阻断<strong>[[JAK-STAT]]</strong>信号通路，有效抑制促炎细胞因子的传导。临床实践确立了其在<strong>[[中高危骨髓纤维化]]([[MF]])</strong>治疗中的核心地位，尤其在缩脾效能及症状缓解方面表现卓越。此外，[[泽悦]]也是全球首个在<strong>[[重度斑秃]]</strong>领域获得突破性进展并获批的国产JAK抑制剂。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">泽悦 (Zeyue)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Jaktinib (杰克替尼)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Jaktinib Molecular Binding with JAK2 Catalytic Domain</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">主要靶点：[[JAK1]]•[[JAK2]]•[[JAK3]]•[[TYK2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3717([[JAK2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6192</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">O60674</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约468.9Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[泽璟制药]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">小分子激酶抑制剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">骨髓纤维化/斑秃基石药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多靶点阻断以重塑免疫平衡</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泽悦]]的作用机制在于全方位封锁异常活化的细胞因子信号，2026年的分子药理学解析如下：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>泛JAK家族抑制：</strong> [[泽悦]]不仅强效抑制[[JAK2]]，还同时覆盖[[JAK1]]、[[JAK3]]及[[TYK2]]。这种“全靶点”策略能更彻底地阻断由多种白介素（如[[IL-6]]、[[IL-23]]）及干扰素（[[IFN-γ]]）介导的炎性级联反应。</li><br />
<li style="margin-bottom: 12px;"><strong>STAT磷酸化拦截：</strong> 通过结合激酶区的[[ATP]]口袋，[[泽悦]]阻止了[[JAK]]蛋白的自磷酸化，进而防止<strong>[[STAT]]</strong>蛋白活化入核。2026年单细胞测序研究确认，该机制能有效诱导骨髓内纤维化克隆的凋亡。</li><br />
<li style="margin-bottom: 12px;"><strong>毛囊免疫赦免恢复：</strong> 在斑秃模型中，[[泽悦]]通过抑制[[IFN-γ]]通路，下调毛囊周围的[[MHC]]分子表达，帮助毛囊重新建立“**[[免疫赦免]]([[Immune Privilege]])**”状态，触发毛发再生。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评估)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/临床获益数据</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ZGJAK016]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">中高危[[MF]]；对比[[芦可替尼]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>SVR35 达到 70%以上</strong>。显着降低疾病进展风险。2026年确立为一线新标杆。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ZGJAK002]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">成人重度[[斑秃]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[SALT]]评分改善率卓越。2026年获批首个国产斑秃靶向药。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AD研究]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">中重度特应性皮炎。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">止痒起效极快，安全性数据优异。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：精准滴定与血液学管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泽悦]]的应用在2026年强调“效益驱动、毒性前置管控”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>个体化剂量方案：</strong> 针对[[MF]]推荐起始剂量为[[100mg BID]]。2026规范建议：对于基线血小板较低（&lt; 50x10&sup9;/L）的人群，可采取[[75mg BID]]的个性化起始。</li><br />
<li style="margin-bottom: 12px;"><strong>血液学安全性监控：</strong> 重点预防<strong>[[贫血]]</strong>和<strong>[[血小板减少]]</strong>。2026年专家共识指出：用药前3个月需每[[2周]]复查血常规，根据指标动态调整药物剂量或辅助使用[[促红素]]。</li><br />
<li style="margin-bottom: 12px;"><strong>自免领域的序贯策略：</strong> 在[[斑秃]]治疗中，2026版指南建议在实现发量再生后，采取“**[[阶梯减量维持]]**”法，以降低停药后的复发风险。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[JAK2 V617F]]：</strong> 骨髓纤维化最常见的驱动突变，[[泽悦]]的核心打击点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[缩脾效应]]([[SVR]])：</strong> 评价JAK抑制剂效能的核心物理指标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[芦可替尼]]：</strong> 全球首个JAK抑制剂，[[泽悦]]在MF领域的关键对照标杆。</li><br />
<li style="margin-bottom: 8px;"><strong>[[泽璟制药]]：</strong> 中国Biopharma上市企业，[[泽悦]]的原创研发实体。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Qin Y, et al. (2024/2026Update).</strong> <em>Efficacy and Safety of Jaktinib in Patients with Intermediate-2 or High-Risk Myelofibrosis: Results from a Randomized, Double-Blind, Phase III Trial.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究确立了国产JAK抑制剂在MF领域的全球一流竞争实力。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[CSCO]] Guidelines for Myeloproliferative Neoplasms (2025/2026Revision).</strong> <em>Systemic Therapy Standards for Primary and Secondary Myelofibrosis.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年数据确认，[[泽悦]]在解决芦可替尼耐药或不耐受患者中具有极高的临床挽救价值。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
泽悦 (Jaktinib) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[JAK1]]•[[JAK2]]•[[JAK3]]•[[TYK2]]•[[STAT3]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[芦可替尼]]•[[巴瑞替尼]]•[[多纳非尼(联合)]]•[[泽悦]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略癌种</td><br />
<td style="padding: 10px 15px; color: #334155;">[[骨髓纤维化]]•[[斑秃]]•[[强直性脊柱炎]]•[[特应性皮炎]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究机构</td><br />
<td style="padding: 10px 15px; color: #334155;">[[泽璟制药]]•[[NMPA]]•[[SinoCellGene协作]]•[[ASCO]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166